Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Acquisitions & Divestments (2020 - 2025)

Historic Change in Acquisitions & Divestments for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $74.1 million.

  • Lyell Immunopharma's Change in Acquisitions & Divestments fell 4442.95% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.5 million, marking a year-over-year decrease of 2337.49%. This contributed to the annual value of $548.9 million for FY2024, which is 1728.01% down from last year.
  • Per Lyell Immunopharma's latest filing, its Change in Acquisitions & Divestments stood at $74.1 million for Q3 2025, which was down 4442.95% from $93.5 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Change in Acquisitions & Divestments ranged from a high of $204.2 million in Q1 2021 and a low of $70.3 million during Q4 2021
  • In the last 5 years, Lyell Immunopharma's Change in Acquisitions & Divestments had a median value of $133.4 million in 2024 and averaged $135.3 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Change in Acquisitions & Divestments tumbled by 6580.79% in 2021, and later soared by 7823.88% in 2023.
  • Lyell Immunopharma's Change in Acquisitions & Divestments (Quarter) stood at $70.3 million in 2021, then surged by 57.68% to $110.9 million in 2022, then soared by 40.78% to $156.1 million in 2023, then fell by 20.77% to $123.7 million in 2024, then tumbled by 40.07% to $74.1 million in 2025.
  • Its last three reported values are $74.1 million in Q3 2025, $93.5 million for Q2 2025, and $154.1 million during Q1 2025.